RISK FACTORS

drug candidate. In addition, market acceptance and sales of our drug candidates will depend
significantly on the availability of adequate coverage and reimbursement from third-party
payers for our drug candidates and may be affected by existing and future health care reform
measures.

We may explore the licensing of commercialization rights or other forms of collaboration
worldwide, which will expose us to additional risks.

Non-PRC markets are a component of our growth strategy. If we fail to obtain licenses
or enter into collaboration arrangements with third parties in these markets, or if these parties
are not successful, our revenue-generating growth potential will be adversely affected.
Moreover, international business relationships subject us to additional risks that may materially
and adversely affect our ability to attain or sustain profitable operations, including:

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

(cid:129)

efforts to enter into collaboration or licensing arrangements with third parties in
connection with our international sales, marketing and distribution efforts which
may increase our expenses or divert our management’s attention from the
acquisition or development of drug candidates;

changes in a specific country’s or region’s political and cultural climate or economic
condition;

differing regulatory requirements for drug approvals and marketing internationally;

difficulty of effective enforcement of contractual provisions in local jurisdictions;

potentially reduced protection for IP rights;

potential third-party patent rights;

unexpected changes in tariffs, trade barriers and regulatory requirements;

economic weakness, including inflation or political instability;

compliance with tax, employment,
traveling abroad;

immigration and labor laws for employees

the effects of applicable non-PRC tax structures and potentially adverse tax
consequences;

currency fluctuations, which could result
reduced revenue, and other obligations incidental
country;

in increased operating expenses and
to doing business in another

– 68 –

